LEO Pharma secures global rights to JW1601 in $402m deal with JW Pharmaceutical

LEO Pharma, a leading Danish pharmaceutical company, has acquired global exclusive rights to the atopic dermatitis drug JW1601 from JW Pharmaceutical (JWP), in a significant ... Read More